[18F]LY4214835

[18F]LY4214835 is a fluorine-18 labeled small molecule radiopharmaceutical developed by Eli Lilly and Company for use as a diagnostic imaging agent in oncology. Functioning as a positron emission tomography (PET) tracer, it is designed to selectively accumulate in neoplastic tissues, enabling the non-invasive visualization and characterization of cancer-related biological signals. The compound is currently in Phase 1 clinical development, where it is being evaluated for safety, biodistribution, and radiation dosimetry in both healthy volunteers and patients with various types of cancer. As a diagnostic tool, [18F]LY4214835 is intended to support the detection, staging, and monitoring of neoplasms rather than serving a therapeutic purpose.